Abrol SR prolonged-release capsules 75 mg blister 10 pcs.

• active ingredient: ambroxol hydrochloride (ampoxol hydrochloride);
• Each prolonged-release capsule contains: ambroxol hydrochloride 75 mg;
• excipients: microcrystalline cellulose, xanthan gum, hypromellose, hydroxypropylcellulose, magnesium stearate, hard gelatin capsule*; *hard gelatin capsule: gelatin, purified water, titanium dioxide (E 171).

• Hypersensitivity to the components of the drug.
• Gastric and duodenal ulcers, cramps of any etiology.
• I trimester of pregnancy or breastfeeding.
• Childhood.

Adults 1 tablet per day in the morning or evening after meals. Duration of treatment – up to 14 days. You should consult a doctor if the symptoms of the disease last longer than 14 days and / or worsen despite taking Abrol ® SR.

Pregnant women

Ambroxol penetrates the placental barrier. The drug is not recommended for use in the first trimester of pregnancy. In the second and third trimesters of pregnancy, Abrol ® SR is used only when the expected benefit to the mother outweighs the potential risk to the fetus.

Ambroxol penetrates into breast milk, so it is not recommended to use the drug during breastfeeding.

Children

They don’t take it.

Drivers

No effect.

There are currently no reports of overdose symptoms.

In case of overdose symptoms when the therapeutic dose is significantly exceeded, symptomatic treatment is necessary.

As a rule, the drug is well tolerated by patients.

Gastrointestinal tract: heartburn, dyspepsia, nausea, vomiting, diarrhea.

Immune system, skin and subcutaneous tissue disorders: rash, urticaria, angioedema, anaphylactic reactions (including anaphylactic shock) and allergic reactions.

If skin or mucous membrane lesions progress, treatment with the drug should be discontinued immediately and a doctor should be consulted.

Sometimes weakness, headache, dry mouth and respiratory tract, rhinorrhea and dysuria may occur.

Severe skin reactions, such as Stevens-Johnson syndrome and Lyell’s syndrome, are extremely rare. They can usually be explained by the severity of the underlying disease or concomitant medications.

As a result of the use of ambroxol, the concentration of antibiotics (amoxicillin, cefuroxime, erythromycin) in bronchopulmonary secretions and sputum increases.

There are no reports of clinical interactions with other drugs.

Store at a temperature not exceeding 25 °C in a dry place, protected from light. Keep out of the reach of children.